Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Austin, United States, June 09, 2026 (GLOBE NEWSWIRE) -- "The Viral Vector Production (Research-use) Market was valued at USD 1.95 billion in 2025 and is projected to reach USD 8.26 billion by 2035, ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

CGT upstream bioprocessing presents unique scale-up and monitoring challenges that differ fundamentally from conventional mAb ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

A Korean research team has developed a new viral vector technology that significantly improves the production efficiency of next-generation cell and gene therapies known as CAR immune cell therapies, ...

Lentiviral vectors are derived from lentiviruses such as HIV-1 and serve as potent gene delivery vehicles due to their capacity to integrate stably into the host genome and transduce both dividing and ...